Court-Ordered Ivermectin: Survival Rate Stuns Gatekeepers

Medical staff in hazmat suits attend to a patient in a hospital bed — Photo: Kobkit Chamchod / Shutterstock

An attorney told a Senate panel that 69 of 72 court-ordered ivermectin patients survived, renewing a fierce fight over who controls care in America’s hospitals.

Story Highlights

Attorney Ralph Lorigo testified he won 72 court orders for ivermectin; 69 patients survived.
Lorigo said families from 40 states sought help to override hospital refusals.
Major medical groups still advise against ivermectin for COVID-19 outside trials.
Courts have often deferred to hospitals in later rulings, limiting such orders.

Attorney’s Senate Testimony Cites 69 Survivors Out of 72 Court-Ordered Treatments

Ralph Lorigo told Senator Ron Johnson’s roundtable that he represented 212 families across 40 states during the pandemic. He said courts ordered hospitals to give ivermectin in 72 cases, and only three patients died. That implies 69 survivors, a roughly 95.8 percent survival rate among that group, according to coverage of the hearing. The figure reflects his case summaries from litigation, not an audited medical registry. The panel focused on hospital protocols, patient rights, and whether institutions blocked reasonable options.

Lorigo framed the disputes as fights over consent and autonomy when hospitals refused off-label treatment. He described families turning to emergency courts while loved ones declined on ventilators. He argued that judges can and should step in when hospitals slam the door on options that bedside physicians or outside consultants support. He said the goal was not chaos, but a lifeline when standard protocols failed and time was short. His testimony stressed urgent access, not long research timelines.

Medical Guidelines Still Advise Against Ivermectin for COVID-19

Large guideline bodies continue to disagree with using ivermectin for COVID-19 treatment. The World Health Organization advises against ivermectin except in clinical trials, reflecting a review of available studies and trial quality concerns. The Infectious Diseases Society of America also recommends against ivermectin for both hospitalized and outpatient settings outside trials. Several meta-analyses report no clear benefit on survival, hospitalization length, or ventilation need in randomized trials, reinforcing those positions.

These medical reviews judge drug value by controlled evidence, not courtroom results. They weigh trial design, sample size, dosing, and timing. They place less weight on individual stories or emergency orders. That creates a sharp divide. Families point to patients who improved after a court win. Medical groups point to aggregate data that shows no proven gain. This gap fuels the ongoing fight over whether hospitals should flex to patient demands when evidence is mixed or negative.

Courts Split Early, Then Tilted Back Toward Hospital Control

Early in the pandemic, some trial judges ordered hospitals to allow ivermectin. As appeals mounted, higher courts in several states reversed or narrowed such orders. The Wisconsin Supreme Court limited compelled treatment in a closely watched case. Other appellate rulings stressed deference to medical judgment and hospital policies rather than judicial mandates. Legal analyses note a longer-run shift: emergency wins became rarer as courts sought consistent standards and reduced liability risks.

This legal arc matters for future care fights. If judges avoid directing treatment, families have fewer tools when hospitals refuse off-label options. If lawmakers codify stronger patient-choice rights, hospitals may face new duties to allow outside prescribers or transfers. President Trump’s administration has pushed for medical freedom and transparency, but state law and hospital bylaws still shape bedside choices. Clear rules can protect both patient autonomy and doctor judgment when crises hit again.

What Conservatives Should Watch Next: Access, Transparency, and Liability

Congress can press for open data on contested cases so the public can see outcomes, not just anecdotes. A transparent, de-identified registry of court-ordered treatments could confirm survival rates, timing, and co-treatments. States can affirm a patient’s right to try lawful, off-label drugs with informed consent when standard care fails. Hospitals can allow credentialed outside doctors under tight protocols. These steps defend individual liberty while keeping safety checks in place.

Families deserve a say when loved ones are fading and options are few. Hospitals should not hide behind blanket rules or politics. Judges should not be forced into medicine unless a hospital blocks reasonable consent. Lorigo’s survival tally, even if not a clinical trial, signals that some patients may have benefited, or at least that families felt heard when courts intervened. The path forward is simple: sunlight, choice, and accountability—so next time, patients are partners, not obstacles.